A systematic review and meta-analysis evaluated randomized controlled trials on pharmacological treatments for anxiety in adults aged 60 and older, identifying 19 eligible studies with 2,336 participants (68% women). The primary outcomes included reductions in anxiety symptoms, treatment response, or remission. Antidepressants were found to be more effective than placebo or waitlist controls in reducing anxiety symptoms (standardized mean differences –1.19), with moderate certainty of evidence despite high heterogeneity. They were also more effective in achieving treatment response or remission (risk ratio 1.52), though this evidence had low certainty and low heterogeneity. Subgroup analysis showed that selective serotonin reuptake inhibitors led to greater symptom reduction than serotonin–norepinephrine reuptake inhibitors, though no difference was observed in response or remission rates. Evidence for benzodiazepines was very uncertain and marked by high risk of bias. Other drug classes could not be adequately analyzed. Overall, antidepressants appear effective and reasonably safe for treating anxiety in older adults, while evidence for benzodiazepines remains weak, helping inform evidence-based clinical practice. Anxiety is common in older adults. Source: https://www.thelancet.com/
Early-life sugar restriction during pregnancy and infancy was associated with a 34% lower risk of…
Higher levels of physical activity were associated with lower risks of all-cause dementia, Alzheimer’s disease,…
In US adults aged ≥65 years, overweight and class I–II obesity were associated with lower…
In community-dwelling older adults without prior cardiovascular disease (CVD), new or persistent heart stress (HS)—defined…
In the German multicenter study of 5,521 patients with colorectal cancer (CRC), the apparent survival…
In adults aged 75 years or older without a history of atherosclerotic cardiovascular disease (ASCVD)…
This website uses cookies.